Stem cells aim to restore sexual function after prostate cancer surgery

NCT ID NCT04594850

Completed Disease control Sponsor: Pharmicell Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a single injection of stem cells (from the patient's own bone marrow) into the penis to treat erectile dysfunction in men who had their prostate removed due to cancer. Fifty-four men participated. The study measured changes in erectile function scores using a standard questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous bone marrow-derived mesenchymal stem cells
What this could lead to: If successful, this could offer a new treatment option for men with erectile dysfunction after prostate cancer surgery.
What could go wrong: This is an early-phase trial with only 54 participants. The treatment may not improve erectile function significantly, and long-term safety is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERECTILE DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

erectile dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERECTILE DYSFUNCTION

Contacts and locations

Locations

Asan medical center

Seoul, South Korea
Ewha womans university medical center

Seoul, South Korea
Samsung medical center

Seoul, South Korea
Seoul ST. Mary's hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.